DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety Study of Levocetirizine and Fexofenadine

Information source: Charite University, Berlin, Germany
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Allergic Rhinitis

Intervention: Levocetirizine (Drug); Fexofenadine (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Charite University, Berlin, Germany

Official(s) and/or principal investigator(s):
Marcus Maurer, MD, Principal Investigator, Affiliation: Charite Universitätsmedizin Berlin

Summary

Primary objective: The comparative efficacy of levocetirizine 5 mg once daily with that of fexofenadine 60 mg twice daily against histamine induced wheal, flare and itch responses measured at 0 (baseline), 0. 5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours. Secondary objectives:

1. The areas under the curves (0 , 12 hours, 12 - 24 hours and 0 - 24 hours) for

inhibition of histamine induced wheal, flare and itch responses for levocetirizine 5 mg once daily and fexofenadine 60 mg twice daily. 2. The number of individuals with peak responses in each 10 percentile (Because of the variable absorption of fexofenadine, it is predicted that fexofenadine will have a variable response between individuals). 3. The mean plasma levels of levocetirizine and fexofenadine at 0 (baseline), 0. 5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours.

Clinical Details

Official title: Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once daily with Fexofenadine 60 mg twice daily in the histamine induced wheal- and flare and itch response

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Eighteen (18) healthy male volunteers, including at least 6 persons of Japanese

origin, will be recruited for this study Exclusion Criteria:

- None of the subjects will have taken oral antihistamines, antidepressants,

antipsychotics or corticosteroids or applied topical antihistamines, corticosteroids or mast cell stabilizers to the skin for 2 weeks prior to testing.

- No subject shall perform physical exercise for 4 hours prior to the skin prick

testing.

- Especially, Bronchial asthma, anaphylactic reactions in the history, use of

beta-blockers, skin diseases in the test field are exclusion criteria.

Locations and Contacts

University of Berlin Charité, Berlin 10117, Germany
Additional Information

Starting date: February 2011
Last updated: April 24, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017